Description

Ublituximab is a monoclonal antibody used in the treatment of certain types of blood cancers, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. It works by targeting CD20, a protein found on the surface of B-cells, leading to their destruction.

Interpreter Notes

Interpreters should be aware that Ublituximab may be referred to in various ways, but it is essential to stick to the glossary term in formal contexts. Common variants may include brand names or abbreviations, which should be avoided in clinical discussions to maintain clarity.

Example Sentences

EN: The oncologist recommended Ublituximab as a treatment option for the patient's lymphoma.

ES: El oncólogo recomendó Ublituximab como una opción de tratamiento para el linfoma del paciente.

Common Interpreter Mistakes

Confusing Ublituximab with similar-sounding medications; using incorrect brand names; mispronouncing the term due to unfamiliarity.